| David Montgomery Curtis, DDS | |
|
2855 Campus Dr, Ste 670, Plymouth, MN 55441-2649 | |
| (763) 520-1234 | |
| (763) 520-1233 |
| Full Name | David Montgomery Curtis |
|---|---|
| Gender | Male |
| Speciality | Maxillofacial Surgery |
| Experience | 38 Years |
| Location | 2855 Campus Dr, Plymouth, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265402531 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223S0112X | Dentist - Oral And Maxillofacial Surgery | 10007 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associates In Oral And Maxillofacial Surgery, P.a. | 7416988209 | 3 |
News Archive
The Gutenberg Research College of Johannes Gutenberg University Mainz has chosen to give the 2016 Gutenberg Research Award to American biomedical researcher Dr. Vishva Dixit for his groundbreaking work in the field of programmed cell death.
High levels of testosterone may be a key factor in spreading disease among mice, according to biologists. The findings could help explain why males in a population are often more likely to get infected, and transmit disease.
US HIFU, a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 medical device, has announced its intention to fund a landmark multi-center trial to study focal therapy for localized prostate cancer. Mark Emberton, M.D., (FRCS-Urology), consultant urological surgeon and divisional clinical director of cancer services at University College London Hospital (UCLH), along with Hashim Uddin Ahmed, MRC clinical research fellow, will lead the trial.
Community Health Systems, Inc. today announced that its wholly-owned subsidiary, CHS/Community Health Systems, Inc., has commenced a cash tender offer for any and all of its approximately $934 million outstanding principal amount of 8⅞% Senior Notes due 2015.
Aradigm Corporation today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE) under a U.S. IND. This orphan disease indication is a chronic, severe respiratory disease and there are currently no approved treatments for this disease in the U.S.
› Verified 5 days ago
| Entity Name | Associates In Oral And Maxillofacial Surgery, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578596177 PECOS PAC ID: 7416988209 Enrollment ID: O20050822000717 |
News Archive
The Gutenberg Research College of Johannes Gutenberg University Mainz has chosen to give the 2016 Gutenberg Research Award to American biomedical researcher Dr. Vishva Dixit for his groundbreaking work in the field of programmed cell death.
High levels of testosterone may be a key factor in spreading disease among mice, according to biologists. The findings could help explain why males in a population are often more likely to get infected, and transmit disease.
US HIFU, a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 medical device, has announced its intention to fund a landmark multi-center trial to study focal therapy for localized prostate cancer. Mark Emberton, M.D., (FRCS-Urology), consultant urological surgeon and divisional clinical director of cancer services at University College London Hospital (UCLH), along with Hashim Uddin Ahmed, MRC clinical research fellow, will lead the trial.
Community Health Systems, Inc. today announced that its wholly-owned subsidiary, CHS/Community Health Systems, Inc., has commenced a cash tender offer for any and all of its approximately $934 million outstanding principal amount of 8⅞% Senior Notes due 2015.
Aradigm Corporation today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE) under a U.S. IND. This orphan disease indication is a chronic, severe respiratory disease and there are currently no approved treatments for this disease in the U.S.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Montgomery Curtis, DDS 2855 Campus Dr, Ste 670, Plymouth, MN 55441-2649 Ph: (763) 520-1234 | David Montgomery Curtis, DDS 2855 Campus Dr, Ste 670, Plymouth, MN 55441-2649 Ph: (763) 520-1234 |
News Archive
The Gutenberg Research College of Johannes Gutenberg University Mainz has chosen to give the 2016 Gutenberg Research Award to American biomedical researcher Dr. Vishva Dixit for his groundbreaking work in the field of programmed cell death.
High levels of testosterone may be a key factor in spreading disease among mice, according to biologists. The findings could help explain why males in a population are often more likely to get infected, and transmit disease.
US HIFU, a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 medical device, has announced its intention to fund a landmark multi-center trial to study focal therapy for localized prostate cancer. Mark Emberton, M.D., (FRCS-Urology), consultant urological surgeon and divisional clinical director of cancer services at University College London Hospital (UCLH), along with Hashim Uddin Ahmed, MRC clinical research fellow, will lead the trial.
Community Health Systems, Inc. today announced that its wholly-owned subsidiary, CHS/Community Health Systems, Inc., has commenced a cash tender offer for any and all of its approximately $934 million outstanding principal amount of 8⅞% Senior Notes due 2015.
Aradigm Corporation today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE) under a U.S. IND. This orphan disease indication is a chronic, severe respiratory disease and there are currently no approved treatments for this disease in the U.S.
› Verified 5 days ago
Michael Nelson, Dentist Medicare: Not Enrolled in Medicare Practice Location: 13550 26th Ave N, Plymouth, MN 55441 Phone: 952-929-0641 | |
Dr. Mark Richard Jensen, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 3401 Highway 169 N, Plymouth, MN 55441 Phone: 763-559-0859 Fax: 763-559-4356 | |
Dr. Roger Alan Mondale, D.D S. Dentist Medicare: Medicare Enrolled Practice Location: 10600 Old County Rd. 15, Suite 120, Plymouth, MN 55441 Phone: 763-512-8500 Fax: 763-512-8592 | |
Joseph Youssef Atme, DDS Dentist Medicare: Medicare Enrolled Practice Location: 15650 36th Ave N, #150, Plymouth, MN 55446 Phone: 763-557-0287 Fax: 763-557-0295 | |
Dr. Heather M. Carr, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 3455 Plymouth Blvd, Plymouth, MN 55447 Phone: 763-551-8911 | |
Dr. Shauna Anderson, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 9800 Shelard Pkwy, Suite #130, Plymouth, MN 55441 Phone: 763-525-5011 Fax: 763-525-8943 | |
Dr. Paul Arnesen, Dentist Medicare: Not Enrolled in Medicare Practice Location: 1525 Co Rd 101 N, Plymouth, MN 55447 Phone: 763-475-2820 |